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Abstract
A newly identified gene, p51, is a functional and struc-
tural homologue of the p53 gene and thus a candidate
tumor suppressor gene. To elucidate the role of the p51
gene in lung carcinogenesis, we determined the se-
quences of exon-intron boundaries and the 5X- and 3X-
flanking regions of all the 15 coding exons and per-
formed a mutation analysis, as well as detailed analysis
for gene expression. A frameshift mutation was de-
tected in 1 of 44 lung cancer cell lines, whereas no
mutation was detected in 45 primary lung cancers. Thus,
p51 mutation occurs only in a small subset of lung
cancer. Expression of the p51 gene was detected in 23
of 43 cell lines by Northern blot analysis and 34 of 44 by
reverse transcriptase-polymerase chain reaction
( )RT-PCR analysis. Thus, p51 expression is low or ab-
sent in a subset of lung cancer. The DN isotype of p51
transcripts was dominantly expressed in several cell
lines, particularly in cell lines with high levels of p51
expression. Because the DN isotype encodes a protein
that transdominantly suppresses the transactivation
function of the TA type of p51, it is possible that p51
protein is not functionally active, even in lung cancer
cells with p51 mRNA expression, due to expression of
dominant-negative p51 protein. These results sug-
gested that the p51 gene is inactive in a considerable
proportion of lung cancers. RT-PCR analysis also re-
vealed the presence of a novel type of mRNA transcript,
p51d, which lacks exons 12 and 13 by alternative splic-
ing. The d isotype was expressed in 18 of 44 lung
cancer cell lines and in diverse normal tissues. Further
analysis on p51 expression in cancerous as well as
noncancerous cells will provide us with valuable infor-
mation for the understanding of multiple functions of
the p53 family proteins in human carcinogenesis.
Keywords: p51 gene, p53 family proteins, mutation, alternative splicing, lung
cancer.
Introduction
The p53 tumor suppressor gene plays a key role in human
carcinogenesis through regulating its target genes involved
in cell cycle control and apoptosis in response to cellular
[ ]damage 1 . Inactivation of the p53 gene appears to be the
most common genetic alteration in human cancers and
contributes to the development of over 50% of all human
[ ]cancers 2 . Recently, two of the p53 structural homo-
( )logues, p51 also designated as p40, p63 and p73L and
[ ]p73, were cloned 3–8 . Because both p51 and p73 share
critical functions with p53, including the induction of growth
arrest and apoptosis, it is important to elucidate the func-
tions of the newly identified p53 family of genes in more
detail in association with human carcinogenesis.
To date, mutations of the p51 gene were detected only in
[ ]3 of 101 primary tumors and cancer cell lines 3 . Thus, it
has been considered that p51 mutation occurs rarely in
[ ]human cancers, as in the case of the p73 gene 9,10 .
However, it is still possible that the p51 gene is frequently
mutated in certain types of human cancers, particularly in
cancer cells without p53 mutations. It is also possible that
p51 is inactivated by mechanisms other than genetic alter-
ations, including transcriptional silencing and expression of
a dominant-negative form of the protein. To perform a
detailed molecular analysis on the status of the p51 gene in
human cancer cells, it is indispensable to determine the
genomic structure of the p51 gene. For this reason, we first
determined the genomic structure and designed
intron-based primers for the mutation analysis of the p51
gene.
Yang et al. reported that there are at least 6 major types
( )of p51 mRNA transcripts. Three of them TA isotypes
encode proteins with the transactivation domain, DNA bind-
ing domain, and oligomerization domain, whereas the other
( )three DN isotypes encode proteins without the acidic
[ ]N-terminal domain, which is required for transactivation 7 .
The DN isotypes of p51 proteins were predominantly ex-
pressed in a variety of epithelial cells and could act as
dominant-negative agents toward the TA isotypes of p51
protein as well as p53 protein. Thus, it is also important to
elucidate which types of p51 protein are predominantly
expressed in human cancer cells.
In this study, we performed structural analysis of the p51
gene and its transcripts in human lung cancer cells for the
following reasons. First, the p51 gene has been mapped to
[ ]chromosome 3q28 3 , and comparative genomic hybridiza-
( )tion CGH analysis indicated that this chromosomal region
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[ ]is frequently amplified in human lung cancers 11–16 .
Second, a subset of lung cancers does not have mutated
p53 genes, and responsible genes for the development of
those cancers have not been identified yet. Third, a p51
mutation was previously detected in an undifferentiated
[ ]squamous cell carcinoma of the lung 3 . We determined the
exon-intron structure of the p51 gene and intron sequences
flanking all 15 coding exons and designed 15 sets of
intron-based primers for the mutation analysis of the p51
gene. Then 44 cases of lung cancer cell lines and 45 cases
of primary lung cancers were screened for mutations in the
entire coding region as well as intronic splicing donor and
acceptor sites of the p51 gene by polymerase chain reac-
( )tion-single strand conformation polymorphism PCR-SSCP
analysis. We also performed reverse transcriptase-poly-
( )merase chain reaction RT-PCR analysis to identify the
isotypes of p51 transcripts that are predominantly ex-
pressed in lung cancer cells.
Materials and Methods
Samples
Forty-four lung cancer cell lines, including 33 non–small
( )cell lung carcinomas NSCLCs and 11 small cell lung
( )carcinomas SCLCs were used in this study. NSCLC cell
lines were A427, A549, PC3, PC7, PC9, PC14, LCMS, H23,
H441, H322, Ma1, Ma3, Ma10, Ma12, Ma17, Ma24, Ma26,
Ma29, RERF-LCOK, VMRC-LCD, ABC1, H596, PC10,
LC1-Sq, EBC1, H520, H157, H1155, Ma2, PC13, Lu65,
Lu99A, and Ma25. SCLC cell lines were Lu24, Lu130,
Lu134, Lu135, Lu139, H69, H82, N417, SBC5, H526, and
[ ]H209 17 . Detailed information on these cell lines can be
obtained upon request. Primary lung cancers analyzed were
(obtained from patients with 15 SCLC and 30 NSCLC 15
)adenocarcinomas and 15 squamous cell carcinomas .
High-molecular-weight DNA was prepared from cell lines,
tumors, and adjacent noncancerous tissues as described
[ ]previously 18 . mRNAs of normal lung tissues were ob-
( )tained from Clontech NL1 and patients with lung cancer
( ) ( )qNL2 and NL3 . Poly A mRNA was prepared from cell
lines and normal lung tissues by the Fast Track mRNA
( )isolation kit Invitrogen Corp .
Determination of the Exon-Intron Organization
Genomic DNA fragments covering the p51 gene locus
were obtained by the following procedure. First, several sets
of PCR primers based on the cDNA sequence were de-
signed to construct a contig of genomic DNA fragments
covering the p51 locus. One hundred nanograms of ge-
nomic DNA from human colon cancer cell lines, LoVo and
HCT116, were used for PCR. PCR products were elec-
trophoresed on 0.8% agarose gel, and their sizes were
compared with those of the corresponding cDNA fragments.
Amplified DNA fragments containing introns were se-
quenced to design intron primers. Next, human bacterial
( ) (artificial chromosome BAC DNA Pools Release IV Re-
)search Genetics was screened by PCR with 3 sets of
intron-based primers, which amplified exons 2, 6, and 15 of
( )the p51 gene Table 1 . DNA from a BAC clone containing
the p51 gene locus was isolated according to the supplier’s
protocol and was used to determine the sequences at the
exon-intron boundaries and the 5X- and 3X-flanking regions of
the exons of the p51 gene.
Polymerase Chain Reaction-Single Strand Conformational
Polymorphism Analysis
All samples were examined for mutations in the entire
( X)coding sequence of the p51 gene exons 2–15 and exon 3
by PCR-SSCP analysis. Each exon was amplified by PCR
with primer pairs shown in Table 1. Fifty nanograms of
genomic DNA templates were suspended in a total volume
(of 20-mL PCR buffer containing 10 mmol/L Tris–HCl pH
)9.0 , 50 mmol/L KCl, 1.5 mmol/L MgCl , 100 nmol/L of2
each primer, 200 mmol/L of each deoxynucleotide triphos-
[32 ] (phate, 1.5 mCi of a- P dCTP Amersham Pharmacia
) (Biotech , and 0.5 U Taq DNA polymerase Amersham Phar-
)macia Biotech . PCR conditions were as follows; 30 sec-
onds at 958C, 30 seconds at 558C or 608C, and 90 seconds
at 728C for 35 cycles, followed by 10 minutes at 728C.
Table 1. Primer Sequencesa for Amplification of Individual Exons of the p51 Gene.
X X X X( ) ( ) ( )Exon Sense Primer Sequence 5 -3 Antisense Primer Sequence 5 -3 Size of PCR Product bp
2 GGAAAGAAAGTTATTACCGATCCA atattttgaccacccacatttacc 163
3 cctttccatgcctaactcact gactgaagagaaagcctgtgc 201
X3 CAGAAGAAAGGACAGCAGCAT tgaccgagaaccgcaaatacg 173
4 ggctaatattggggtttctgg aactgggaagggggaaaaatc 376
5 catgcagctctaaaaagtgga aggtgggtctcaaacaaaaat 376
6 ggctatgggatctgttcgtt tcagtccatagaggtgttgtt 318
7 cttaaatagagggtagaactgag cactttgccctctgctcgtg 252
8 gggaagtggaagtggtagatc caccccattctccaacatctg 286
9 catcttccactccttattgc actgtaaaagcccattcaaag 380
10 ggattgaccacacttctaacag gtcactcatgcctcctaaaa 248
11 ccgtgctcaccatcatttcca agctagcctgttcatccttca 243
12 tgatggcagtaaccctttttg agtatccgccctccaccatcc 256
13 ggcatccaagggcaaaata gggcatgacaaaaacaaat 313
14 ctccctgttttcattctccat TAGCCTCTTACTTCTCCTTCC 481
15 ttttgtctggttcctctctgc TGTCTTCAAGTCCTGTTTATG 252
aUpper case letters correspond to exons and lower case letters to introns.
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SSCP analysis was performed in the low pH buffer system
that showed improved separation of long mutant fragments
( ) [ ]of up to 800 base pairs bp 19 . PCR products were
denatured and loaded on nondenaturing polyacrylamide gel
(containing 5% polyacrylamide 99:1 acrylamide to bisacryl-
) (amide and TPE 30 mmol/L Tris, 20 mmol/L PIPES, and 1
)mmol/L Na EDTA; pH6.8 , electrophoresed in TPE buffer2
at 158C, and exposed to Kodak XAR films for 24 to 48 hours
at y808C. PCR products showing different mobilities were
purified and directly sequenced in both directions.
Sequence Analysis
PCR fragments were purified by using QIA quick-spin
( )PCR purification kit QIAGEN and directly sequenced by
using Thermo Sequence dye terminator cycle sequencing
( )pre-mix kits Amersham Pharmacia Biotech and ABI 373S
( )DNA Sequence System Perkin-Elmer . DNA from BAC
clone was sequenced by using the fmol DNA Sequencing
( )System according to the supplier’s protocol Promega .
Southern and Northern Blot Analyses
Southern and Northern blot analyses were carried out
[ ]under the stringent condition described previously 20 . Ge-
nomic DNA was digested with EcoRI and electrophoresed
for Southern blot analysis. The cDNA fragment correspond-
(ing to nucleotide 170–781 of p51A cDNA Accession No.
)AB016072 in Genbank was used for hybridizations as a
probe.
Reverse Transcriptase-Polymerase Chain Reaction Analy-
sis
Randomly primed cDNAs were reverse-transcribed from
0.5 mg mRNAs by using SuperScript II Rnase H-Reverse
Figure 1. Intronic sequences surrounding the p51 coding exon. Nucleotide numbers corresponding to the sequences of
a b ( )p51B, DNp63g , or p51A cDNA Genbank Accession Nos. AB016073, AF075429, and AB016072 are shown above the
boxes. More detailed information of these sequences have been submitted to Genbank/EMBL/DDBJ and have been
assigned the Accession Nos. AF116756 to AF116770.
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( )Figure 2. Mutation of the p51 gene in a lung cancer cell line. A
Mutation of the p51 gene detected by PCR-SSCP. In exon 5, an SSCP
( )variant was detected in a squamous cell carcinoma cell line, EBC1. B
Mutation of the p51 gene detected by direct sequencing. In EBC1, one
base of adenine was inserted in codons 193–194 of exon 5, resulting in
( )a frameshift of one allele underlined . Normal sequence in H596 is
shown as a control.
( )Transcriptase Gibco BRL in a 20-mL mixture according to
the supplier’s protocol. One microliter of the cDNA conver-
sion mixture was amplified by PCR in a 10-mL reaction
mixture. PCR conditions were as follows: 30 seconds at
958C, 30 seconds at 558C or 608C, and 90 seconds at 728C
for 35 cycles, followed by 10 minutes at 728C. The following
primers were used: TA, 5X-ATGTCCCAGAGCACACAG-3X
and 5X-AGCTCATGGTTGGGGCAC-3X; DN, 5X-CAGACTC-
AATTTAGTGAG-3X and 5X-AGCTCATGGTTGGGGCAC-3X;
a and b, 5X-GACTTATGAAATGCTGTTGAA-3X and
5X-TCGCACAGCATCAATAACACG-3X; g, 5X-GACTTATGA-
AATGCTGTTGAA-3X and 5X-CGTCAGATTGTTTTG-
GAGTTT-3X. PCR products were electrophoresed on 2.0%
agarose gel and stained with ethidium- bromide.
Results
Genomic Structure of the p51 Locus
It was previously shown that the p51 gene consisted of
[ ]16 exons and 15 introns 7 . Exon 1 is a noncoding exon,
whereas all others are coding exons. Genomic structure of
exons 2 to 15 was determined by the following methods. A
remarkable conservation of exon-intron organizations be-
tween two of the p53 family genes, p53 and p73, permitted
us to estimate intron positions of the p51 gene. We there-
fore designed PCR primers that would specifically anneal to
regions in possible contiguous exons of the p51 gene.
Genomic DNA fragments that contained introns 2, 5, 6, 7, 8,
9, and 15 were successfully amplified and sequenced to
design sets of intron-based primers that specifically ampli-
fied exons 2, 6, 7, 8, 9, and 15. Then, these sets of primers
were used to screen a BAC library. A BAC clone, 224P11,
covering exons 2 to 15 of the p51 locus, was obtained and
used to determine the sequences of the remaining flanking
introns.
It was previously shown by the structural analysis of p51
cDNA that there are two different start codons and two
[ ]different stop codons in the p51 gene 7,8 . The ATG start
codons were located in exons 2 and 3X, and the stop codons
were located in exons 14 and 15. The structure determined
in this study was consistent with the one determined by
[ ]Yang et al. 7 . The putative transactivation domain, DNA
binding domain, and oligomerization domain were encoded
in exons 2 to 3, exons 4 to 8, and exons 9 to 10, respec-
tively. Two major splicing forms of the p51 gene, p51A and
( )p51B also designated as TAp63g and TAp63a , were
derived from exons 2 to 10 and 15, and exons 2 to 14,
respectively. The sequences of whole exons in the BAC
clone were identical to those of the p51 cDNAs, and all
[ ]exon-intron junctions followed the GT–AG rule 21 . The
boundary sequences of each exon-intron are shown in
Figure 1. Comparison of the genomic organization between
p51 and the other two p53 family genes revealed that the
exon boundary positions and exon sizes of the p51 gene
were highly homologous to those of the p53 and p73
genes. In contrast, the homologies in the size and sequence
of introns were not so high among these three genes
[ ]22,23 .
Genetic Alterations of the p51 Gene in Lung Cancers
PCR amplification of genomic DNA from cell lines and
primary tumors was performed by using the intron-based
( )primers for each of the 15 coding exons Table 1 . The size
of each PCR fragment was less than 500 bp and was
[ ]suitable for SSCP analysis in the low pH buffer system 16 .
Forty-four lung cancer cell lines and 45 primary lung can-
cers were analyzed for p51 mutations and polymorphisms.
A mutation was detected in a squamous cell carcinoma cell
( )line, EBC1 Figure 2 . Sequence analysis of DNA from
Table 2. Polymorphisms of the p51 Gene.
aLocation Sequence Codon Amino Acid Allele Frequency
( )Intron 5 q34 bp from exon 5 T /G 0.89 /0.11
( )Intron 5 q42 bp from exon 5 G /A 0.92 /0.08
Exon 6 C /T 248 Val /Val 0.98 /0.02
( )Intron 8 y22 bp from exon 9 A /G 0.88 /0.12
aAllele frequency was determined in 44 lung cancer cell lines.
Neoplasia v Vol. 1, No. 1, April 1999
p51 Mutation and Expression in Lung Cancer Tani et al. 75
EBC1 revealed one base insertion of adenine at codons
( )193–194 AAAAAA to AAAAAAA . This insertion produces
a frameshift mutation in the DNA binding domain, resulting
in predicted synthesis of truncated p51 of 195 amino acids.
The wild type allele was retained in this cell line. The p53
( )gene was also mutated in EBC1 cells Table 3 .
Four different types of genetic polymorphisms were de-
tected. A silent polymorphism was found at codon 248 in
exon 6, and three others were located in introns 5 and 8
( )Table 2 . Thus, there was no genetic polymorphism by
which p51 protein with different amino acid sequence could
be expressed.
We further searched for genetic alterations in the p51
locus by Southern blot analysis. There were no amplifica-
tion, homozygous deletion, and rearrangement of the p51
( )gene in 42 lung cancer cell lines data not shown .
Expression of the p51 Transcripts in Lung Cancers
We first examined the expression of the p51 gene in lung
cancer cell lines by Northern blot analysis. p51 transcripts
( )Figure 3. Expression of the p51 gene in lung cancers. A Northern blot analysis of the p51 gene in lung cancer cell lines.
( )Two major transcripts 4.4 kb and 3.8 kb are indicated by arrowheads. The membrane was rehybridized with a human
( ) ( )b-actin probe Clontech . B RT-PCR analysis using primers that specifically amplified the TA, DN, a and b , and g
isotypes of p51 transcripts. By using these primers, the TA, DN, a , b , and g types were detected as PCR products of 629
bp, 440 bp, 702 bp, 608 bp, and 191 bp, respectively. A novel isotype, d , was found as a PCR product of 453 bp.
( )Expression of a control housekeeping gene GAPDH is shown in the bottom.
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were detected in 23 of 43 cell lines. In each cell line, major
transcripts of either 4.4 kb or 3.8 kb in size were detected.
The levels of p51 expression were variable among cell lines
and relatively high in H322, Ma3, Ma10, Ma24, H596, PC10,
( )and LC1-Sq Figure 3A, Table 3 . Cell lines with high levels
of p51 expression were derived either from adenocarcinoma
or squamous cell carcinoma and were not from large cell
carcinoma or small cell carcinoma. However, apparently no
correlation was observed between the level of expression
and the histology of cell lines. The p53 gene is not mutated
( )in 7 A427, A549, Ma12, Ma17, Lu99A, Lu24, and H209 of
( )the 43 cell lines examined Table 3 . Among them, a low
level of p51 expression was detected in Ma12 only, and p51
transcripts were not detected in the remaining 6 cell lines.
Thus, it is possible that the p51 gene is not expressed in
most of lung cancer cells with wild type p53 expression.
Up to the present, six of alternatively spliced p51 tran-
scripts have been identified, and they encode proteins with
( )two different N termini TA and DN and three different C
( ) [ ]termini a , b, and g 7 . To obtain more detail information
on p51 expression in lung cancers, we performed RT-PCR
analysis with 4 sets of primers that specifically amplified the
( )TA, DN, a and b, and g isotypes Figure 3B . Expression
patterns of these isotypes in each cell line are summarized
Table 3. Analysis of p51 Transcripts in Human Lung Cancer Cell Lines.
a b c( )Sample Histology Level of Expression Size of mRNA kb Pattern of Expression p53 Status
TA DN a b g d
A427 AdC y y y y y y y wt
A549 AdC y " y y y y y mut
PC3 AdC q 3.8 q q q q q q mut
PC7 AdC q 4.4 q y " y " q mut
PC9 AdC y " y y y y y mut
PC14 AdC y y y y y y y mut
LCMS AdC y y y y y y y mut
H23 AdC y " y y y " y mut
H441 AdC q 4.4 q " q q q q mut
H322 AdC qq 4.4 " q q q q q mut
Ma1 AdC y " y y y " y mut
Ma3 AdC qq 3.8 q q q q q q mut
Ma10 AdC qq 3.8 " q q y q q mut
Ma12 AdC q 4.4 " y y y " y wt
Ma17 AdC y y y y y y y wt
Ma24 AdC qq 4.4 q q q q q q mut
Ma26 AdC q 4.4 q y " y " q mut
Ma29 AdC q 4.4 q y " q q q mut
RERF-LCOK AdC q 4.4 " y " y " q mut
VMRC-LCD AdC y " y y y y y mut
ABC1 AdC q 3.8 q q q " q q mut
H596 ASC qq 4.4 q q q q q q mut
PC10 SqC qq 4.4 q q q q q q mut
LC1-Sq SqC qq 4.4 q q q q q q mut
EBC1 SqC q 4.4 " y y y y y mut
H520 SqC y " y y y y y mut
H157 SqC y " y y y y y mut
H1155 LCC y y y y y y y mut
Ma2 LCC y y y y y y y mut
PC13 LCC ND y y y y y y mut
Lu65 LCC q 4.4 q y " y y " mut
Lu99A LCC y y y y y y y wt
Ma25 LCC y " y y y y y mut
Lu24 SCC y " y " y y " mut
Lu130 SCC q 4.4 " y y " " y mut
Lu134 SCC q 4.4 " y " y y " mut
Lu135 SCC y " y y y y y mut
Lu139 SCC q 4.4 y y y y y y mut
H69 SCC q 4.4 " y y y y y mut
H82 SCC y " y y y y y mut
N417 SCC y y y y y y y mut
SBC5 SCC q 4.4 q " " y y " mut
H526 SCC q 4.4 y y y y y y mut
H209 SCC y y y y y y y wt
NL1 Normal ND q q y y " "
NL2 Normal ND " " y y " y
NL3 Normal ND " " y y q q
aLevel of expression was analyzed by Northern blot analysis. ND, not done.
bPattern of expression was analyzed by RT-PCR.
c [ ]These data were obtained from IARC p53 database 24 . Our unpublished data are also included.
AdC, adenocarcinoma; ASC, adenosquamous cell carcinoma; SqC, squamous cell carcinoma; LCC, large cell carcinoma; SCC, small cell carcinoma;
( ) ( )Normal, mRNAs of normal lung tissues were obtained from Clontech NL1 and patients with lung cancer NL2 and NL3 . wt, wild type; mut, mutated.
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in Table 3. The result of RT-PCR analysis was almost
consistent with and similar to that of Northern blot analysis.
Either one or more p51 isotypes were detected in 34 of 44
cell lines. p51 transcripts were also detected by RT-PCR
analysis in all three of normal lung tissues. There was no
correlation between the isotypes expressed and histology of
cell lines. Interestingly, all of 7 cell lines expressing high
levels of p51 expressed the DN isotype that inactivates the
[ ]function of the TA isotype transdominantly 7 . The a and b
isotypes were not detected in normal lung tissues, although
those two isotypes were detected in most lung cancer cell
lines.
We found a novel p51 variant that was amplified by using
(a set of primers specific for the a and b isotypes Figure
)3B, Table 3 . This variant was derived from an alternative
splicing from exon 11 to exon 14, thus, lacked exons 12 and
( )13, and was designated the d isotype Figure 4A . The d
isotype was expressed in 18 of 44 lung cancer cell lines and
2 of 3 normal lung tissues. To examine the tissue distribu-
tion of the d isotype, we performed PCR analysis with
cDNAs from various normal human tissues. Expression of
the d isotype was detected in uterus, thymus, placenta,
mammary gland, and fetal lung, and not detected in kidney,
stomach, small intestine, spleen, bone marrow, brain, spinal
cord, testis, skeletal muscle, adrenal grand, salivary grand,
( )pituitary gland, fetal liver, and fetal kidney Figure 4b .
Among the 7 cell lines without p53 mutations, RT-PCR
products were detected in 3 cell lines, A549, Ma12, and
Lu24. In all the 3 cell lines, the TA isotype but not the DN
isotype was detected, suggesting that the function of
wild-type p53 protein is not suppressed by expression of
dominant-negative p51 protein in these cell lines. Absence
of transcription would be a more common phenomenon in
lung cancer cells with the wild-type p53 gene, as suggested
by Northern blot analysis. In contrast, expression of the DN
isotype was detected in 11 cell lines, and all of them had
mutated p53 gene. Thus, in cell lines with p53 mutations,
the function of the p51 gene might be also inactivated in
part by expression of dominant-negative DN isotype p51
protein.
Although major transcripts of either 4.4 kb or 3.8 kb were
detected by Northern blot analysis, the association between
the sizes and the isotypes of mRNA transcripts is presently
unknown.
( )Figure 4. A Schematic representation of the isotypes of p51 transcripts. The positions of primers for RT-PCR analysis are
( )indicated by arrows. B Tissue distribution of the p51d isotype. Expression of the d isotype in normal human tissues
analyzed by RT-PCR is also shown.
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Discussion
Here we determined the genomic structure of the p51 gene
and, based on this data, we designed 15 sets of primers for
mutation analysis of all the coding sequences of the p51
gene. Previous mutation analysis of the p51 gene showed
that the p51 gene was mutated in a lung squamous cell
( )carcinoma, a head and neck cancer cell line Ho-1-u-1 , and
( ) [ ]a cervical cancer cell line SKG-III 3 . We therefore per-
formed mutation analysis of the p51 gene in human lung
( )cancer. A mutation was detected in only one of 89 1.1%
lung cancers. Thus, mutation of the p51 gene rarely occurs
in lung cancer cells. Mutations detected in the previous
(study were located in exon 4 a lung squamous cell carci-
) ( )noma and Ho-1-u-1 or exon 5 SKG-III . A mutation we
found in this study was also located in exon 5, which
encodes the putative DNA binding domain. These results
suggest that mutations of the p51 gene cluster in the DNA
binding domain, as in the case of mutations in the p53 gene
[ ]24 . The result may also suggest that p51 mutations occur
in a small subset of squamous cell carcinoma and not in
other histological types of lung cancer. Although the present
result indicated that the p51 gene is infrequently mutated in
lung cancers, intron-based primers designed in this study
will be useful for the molecular analysis of the p51 gene in a
variety of human cancers.
Amplification of genes in the 3q28 region has been
suggested to occur in lung cancer cells by the CGH analysis
[ ]11–16 , however, amplification of the p51 gene at 3q28
was not detected by Southern blot analysis. Thus, the p51
gene would not be a target of gene amplification at 3q28 in
lung cancer cells.
Northern blot analysis as well as RT-PCR analysis re-
vealed that the p51 gene is expressed in a large subset of
lung cancer cells and the levels of p51 expression vary
considerably among lung cancer cells. Thus, it would be of
great interest to clarify the association of p51 expression
with biological properties of lung cancer cells. It is possible
that expression of the p51 gene is silenced in a subset of
lung cancer cells by several mechanisms, including DNA
[ ]methylation in the promoter region 25,26 . If so, transcrip-
tional silencing would be one of the mechanisms for p51
inactivation. For this reason, molecular analysis of the pro-
moter region is now in progress in our laboratories.
It is noted that the DN isotype of mRNA transcripts was
expressed in cell lines with high levels of p51 expression.
Because the DN isotype encodes a protein that transdomi-
nantly suppresses the transactivation function of p51A
( )TAp63g as well as p53, it was suggested that the p51
gene, and possibly the p53 gene, is functionally inactivated
in lung cancer cell lines in part by expression of the domi-
nant-negative DNp51 protein. However, because all the cell
lines that express the DN isotype of mRNA transcripts carry
mutated p53 genes, the interaction between the DN isotype
of p51 protein and mutated p53 protein remains unclear.
Further studies are required to resolve this question.
The a and b isotypes were not detected in normal lung
tissues, whereas they were detected in most lung cancer
cell lines. However, the biological significance of this finding
is unclear at present because the functional differences
among a , b, g, and d isotypes are unknown.
Presence of a novel isotype of p51 mRNA transcripts
also indicated that the complexed functions of the p51 gene
can be regulated partly by alternative splicing of the p51
transcripts. Recently, two novel p73 splicing variants, p73g
and p73d, were identified in addition to p73a and p73b. It
has been suggested that p73 provides a complex regula-
tory mechanism to the control of cell growth, because of
different expression patterns for the four splicing variants in
normal and neoplastic cells, and of homodimeric and het-
[ ]rodimeric interactions of various p73 isotypes and p53 27 .
Understanding the interaction between various isotypes of
p51 protein, as well as p53 and p73, would be of great
importance in clarifying the mechanisms for regulation of
cell growth and apoptosis in cancer cells.
Acknowledgements
We thank the following scientists for providing cell lines: Dr.
Y. Hayata of Tokyo Medical College, Drs T. Terasaki and S.
Hirohashi of National Cancer Center Research Institute, Dr.
M. Takada of Izumisano Municipal Hospital, Drs. A. F.
Gazdar and J. D. Minna of the University of Texas, South-
western Medical Center. Cell lines were also obtained from
ATCC. We also thank Dr. H. Sasaki of National Cancer
Center Research Institute for providing cDNAs from various
human normal tissues.
References
[ ] ( )1 Levine AJ 1997 . p53, the cellular gatekeeper for growth and
division. Cell 88, 323–331.
[ ] ( )2 Hollstein M, Sidransky D, Vogelstein B, and Harris CC 1991 . p53
mutations in human cancers. Science 253, 49–53.
[ ]3 Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I,
( )Nimura Y, Nakagawara A, Obinata M, and Ikawa S 1998 . Cloning
and functional analysis of human p51, which structurally and func-
tionally resembles p53. Nat Med 4, 839–843.
[ ]4 Kaghad M, Bonnet H, Yang Y, Creancier L, Biscan J-C, Valent A,
Minty A, Chalon P, Lelias J-M, Dumont X, Ferrara P, McKeon F,
( )and Caput D 1997 . Monoallelically expressed gene related to p53
at 1p36, a region frequently deleted in neuroblastoma and other
cancers. Cell 90, 809–819.
[ ] ( )5 Jost CA, Marin MC, and Kaelin WG Jr 1997 . p73 is a human
p53-related protein that can induce apoptosis. Nature 389, 191–
194.
[ ]6 Trink B, Okami K, Wu L, Spiuranpong V, Jen J, and Sidransky D
( )1998 . A new human p53 homolog. Nat Med 4, 747–748.
[ ]7 Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V,¨
( )Andrews NC, Caput D, and McKeon F 1998 . p63, a p53 homolog
at 3q27–29, encodes multiple products with transactivating,
death-inducing, and dominant-negative activities. Mol Cell 2, 305–
316.
[ ]8 Senoo M, Seki N, Ohira M, Sugano S, Watanabe M, Tachibana M,
( )Tanaka T, Shinkai Y, and Kato H 1998 . A second p53-related
protein, p73L, with high homology to p73. Biochem Biophys Res
Commun 248, 603–607.
[ ]9 Nomoto S, Haruki N, Kondo M, Konishi H, Takahashi T, Takahashi
( )T, and Takahashi T 1998 . Search for mutations and examination
of allelic expression imbalance of the p73 gene at 1p36.33 in
human lung cancers. Cancer Res 58, 1390–1383.
[ ]10 Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M,
( )Wakui S, Yatani R, Aizawa S, and Nakagawara A 1998 . Mutation,
allelotyping, and transcription analyses of the p73 gene in prostatic
carcinoma. Cancer Res 58, 2076–2077.
Neoplasia v Vol. 1, No. 1, April 1999
p51 Mutation and Expression in Lung Cancer Tani et al. 79
[ ]11 Reid T, Petersen I, Holtgreve-Grez H, Speicher MR, Schrock E, du¨
( )Manoir S, and Cremer T 1994 . Mapping of multiple DNA gain and
losses in primary small cell lung carcinomas by comparative ge-
nomic hybridization. Cancer Res 54, 1801–1806.
[ ]12 Levin NA, Brzoska P, Gupta N, Minna JD, Gray JW, and Christman
( )MF 1995 . Identification of frequent novel genetic alterations in
small cell lung tumors. Cancer Res 54, 5086–5091.
[ ]13 Levin NA, Brzoska PM, Warnock ML, Gray JW, and Christman MF
( )1995 . Identification of novel regions of altered DNA copy number
in small cell lung tumors. Genes, Chromosomes Cancer 13, 175–
85.
[ ]14 Schwendel A, Langreck H, Reichel M, Schrock E, Reid T, Dietel M,¨
( )and Petersen I 1997 . Primary small-cell lung carcinomas and their
metastases are characterized by a recurrent pattern of genetic
alterations. Int J Cancer 74, 86–93.
[ ]15 Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E,
( )and Testa JR 1997 . Comparative genomic hybridization analysis
detects frequent, often high-level, overrepresentation of DNA se-
quences at 3q, 5p, 7p, and 8q in human non-small cell lung
carcinomas. Cancer Res 57, 2116–2120.
[ ]16 Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, Karjalainen A,
( )Tammilehto L, Mattson K, Vainio H, and Knuutila S 1998 . DNA
gains in 3q occur frequently in squamous cell carcinoma of the
lung, but not in adenocarcinoma. Genes, Chromosomes Cancer
22, 79–82.
[ ]17 Kohno T, Otsuka T, Takano H, Yamamoto Y, Hamaguchi M, Ter-
( )ada M, and Yokota J 1995 . Identification of a novel phospholipase
C family gene at chromosome 2q33 that is homozygously deleted
in human small cell lung carcinoma. Hum Mol Genet 4, 667–674.
[ ]18 Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimizu
( )K, Sekiguchi M, Terada M, and Sugimura T 1986 . Transforming
gene from human stomach cancers and a noncancerous portion of
stomach mucosa. Proc Natl Acad Sci USA 83, 3997–4001.
[ ] ( )19 Kukita Y, Tahira T, Sommer SS, and Hayashi K 1997 . SSCP
analysis of long DNA fragments in low pH gel. Hum Mutat 10,
400–407.
[ ]20 Tani M, Shindo-Okada N, Hashimoto Y, Shiroishi T, Takenoshita S,
( )Nagamachi Y, and Yokota J 1997 . Isolation of a novel Sry -related
gene that is expressed in high-metastatic K-1735 murine melanoma
cells. Genomics 39, 30–37.
[ ]21 Breathnach R, Benoist C, O’Hare K, Gannon F and Chambon P
( )1978 . Ovaibumin gene: Evidence for a leader sequence in mRNA
and DNA sequences at the exon-intron boundaries. Proc Natl Acad
Sci USA 75, 4853–4857.
[ ]22 Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R,
( )Smith DI, and Liu W 1998 . Genomic organization and mutation
analysis of p73 in oligodendrogliomas with chromosome 1 p-arm
deletions. Genomics 51, 359–363.
[ ] ( )23 Lamb and Crawford L 1986 . Characterization of the human p53
gene. Mol Cell Biol 6, 1379–1385.
[ ]24 Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores
( )T, Hollstein M, Harris CC, and Montesano R 1998 . IARC Database
of p53 gene mutations in human tumors and cell lines: Updated
compilation, revised formats and new visualisation tools. Nucleic
Acids Res 26, 205–213.
[ ]25 Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC,
( ) XBaylin SB, and Sidransky 1995 . 5 CpG island methylation is
associated with transcriptional silencing of the tumour suppressor
p16/CDKN2/MTS1 in human cancers. Nature Med 1, 686–692.
[ ] ( )26 Tornaletti S, and Pfeifer GP 1995 . Complete and tissue-indepen-
dent methylation of CpG sites in the p53 gene: Implications for
mutations in human cancers. Oncogene 10, 1493–1499.
[ ]27 Laurenzi VD, Costanzo A, Barcaroli B, Terrinoni A, Falco M, Annic-
( )chiarico-Petruzzelli M, Levrero M, and Melino G 1998 . Two new
p73 splice variants, g and d, with different transcriptional activity. J
Exp Med 188, 1763–1768.
Neoplasia v Vol. 1, No. 1, April 1999
